Monogenic causes of chronic kidney disease (CKD) are more prevalent in adults than previously thought, as causative gene variants are found in almost 10% of unselected patients with CKD. Even so, genetic testing in patients with adult-onset CKD is uncommon in clinical practice and the optimal criteria for patient selection remain unclear. A family history of kidney disease emerges as one marker associated with a high diagnostic yield of genetic testing. We present 3 cases of adult-onset CKD with underlying monogenic causes exemplifying different modes of inheritance. Case 1 is a 60-year-old male with slowly progressive CKD initially ascribed to hypertension and diabetes despite a family history with several affected first-degree relatives. A pathogenic MUC1 variant was found, and thus we identified the first Danish family of MUC1-associated autosomal dominant tubulointerstitial kidney disease. Case 2 is a 40-year-old female with nephrocalcinosis, nephrolithiasis, and unexplainable hypercalcemia consistent with vitamin D intoxication. The family history indicated autosomal recessive inheritance, and genetic testing revealed 2 pathogenic CYP24A1 variants in compound heterozygous form associated with idiopathic infantile hypercalcemia. Case 3 is a 50-year-old male with microscopic hematuria, proteinuria, and hearing loss. Electron microscopy of renal biopsy showed thin basal membrane syndrome, and the family history indicated X-linked inheritance. A novel missense variant in COL4A5 was identified, suggesting an atypical late-onset form of X-linked Alport syndrome. This case series illustrates the heterogeneous presentations of monogenic kidney disease in adults and emphasizes the importance of family history for initiating genetic testing to identify underlying monogenic causation. Moreover, we discuss the potential impact of genetic diagnostics on patient management and genetic family counseling.

1.
Freedman
BI
,
Soucie
JM
,
McClellan
WM
.
Family history of end-stage renal disease among incident dialysis patients
.
J Am Soc Nephrol
.
1997 Dec
;
8
(
12
):
1942
5
. .
2.
Freedman
BI
,
Volkova
NV
,
Satko
SG
,
Krisher
J
,
Jurkovitz
C
,
Soucie
JM
,
Population-based screening for family history of end-stage renal disease among incident dialysis patients
.
Am J Nephrol
.
2005 Nov–Dec
;
25
(
6
):
529
35
. .
3.
Song
EY
,
McClellan
WM
,
McClellan
A
,
Gadi
R
,
Hadley
AC
,
Krisher
J
,
Effect of community characteristics on familial clustering of end-stage renal disease
.
Am J Nephrol
.
2009
;
30
(
6
):
499
504
. .
4.
Connoughton
DM
,
Bukhari
S
,
Conlon
P
,
Cassidy
E
,
O’Toole
M
,
Mohamad
M
,
The irish kidney gene project: prevalence of family history in patients with kidney disease in Ireland
.
Nephron
.
2015
;
130
(
4
):
293
301
.
5.
Jurkovitz
C
,
Franch
H
,
Shoham
D
,
Bellenger
J
,
McClellan
W
.
Family members of patients treated for ESRD have high rates of undetected kidney disease
.
Am J Kidney Dis
.
2002 Dec
;
40
(
6
):
1173
8
. .
6.
Akrawi
DS
,
Li
X
,
Sundquist
J
,
Sundquist
K
,
Zöller
B
.
Familial risks of kidney failure in Sweden: a nationwide family study
.
PLoS One
.
2014 Nov
;
9
(
11
):
e113353
. .
7.
Lei
HH
,
Perneger
TV
,
Klag
MJ
,
Whelton
PK
,
Coresh
J
.
Familial aggregation of renal disease in a population-based case-control study
.
J Am Soc Nephrol
.
1998 Jul
;
9
(
7
):
1270
6
. .
8.
Akrawi
DS
,
PirouziFard
M
,
Fjellstedt
E
,
Sundquist
J
,
Sundquist
K
,
Zöller
B
.
Hereditability of end-stage renal disease: a Swedish adoption study
.
Nephron
.
2018
;
138
(
2
):
157
65
.
9.
Vivante
A
,
Hildebrandt
F
.
Exploring the genetic basis of early-onset chronic kidney disease
.
Nat Rev Nephrol
.
2016 Mar
;
12
(
3
):
133
46
. .
10.
Connoughton
DM
,
Hildebrandt
F
.
Personalized medicine in chronic kidney disease by detection of monogenetic mutations
.
Nephrol Dial Transplant
.
2020 Mar
;
35
(
3
):
390
7
.
11.
Mallett
A
,
Patel
C
,
Salisbury
A
,
Wang
Z
,
Healy
H
,
Hoy
W
.
The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia
.
Orphanet J Rare Dis
.
2014
;
9
:
98
. .
12.
Groopman
EE
,
Marasa
M
,
Cameron-Christie
S
,
Petrovski
S
,
Aggarwal
VS
,
Milo-Rasouly
H
,
Diagnostic utility of exome sequencing for kidney disease
.
N Engl J Med
.
2019 Jan
;
380
(
2
):
142
51
. .
13.
Mallet
AJ
,
McCarthy
HJ
,
Ho
G
,
Holman
K
,
Farnsworth
E
,
Patel
C
,
Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders
.
Kidney Int
.
2017 Dec
;
92
(
6
):
1493
506
.
14.
Lata
S
,
Marasa
M
,
Li
Y
,
Fasel
DA
,
Groopman
E
,
Jobanputra
V
,
Whole-exome sequencing in adults with chronic kidney disease: a pilot study
.
Ann Intern Med
.
2018 Jan
;
168
(
2
):
100
9
. .
15.
Connaughton
DM
,
Kennedy
C
,
Shril
S
,
Mann
N
,
Murray
SL
,
Williams
PA
,
Monogenic causes of chronic kidney disease in adults
.
Kidney Int
.
2019 Apr
;
95
(
4
):
914
28
. .
16.
Carriazo
S
,
Perez-Gomez
MV
,
Ortiz
A
.
Hypertensive nephropathy: major roadblock hindering the advance of precision medicine nephrology
.
Clin Kidney J
.
2020
;
13
(
4
):
504
9
.
17.
Kramer
A
,
Boenink
R
,
Noordzij
M
,
Bosdriesz
JR
,
Stel
VS
,
Beltrán
P
,
The ERA-EDTA registry annual report 2017: a summary
.
Clin Kidney J
.
2020
;
13
(
4
):
693
709
. .
18.
Saran
R
,
Robinson
B
,
Abbott
KC
,
Bragg-Gresham
J
,
Chen
X
,
Gipson
D
,
US renal data system 2019 annual data report: epidemiology of kidney disease in the United States
.
Am J Kidney Dis
.
2020
;
75
(
1 Suppl 1
):
A6
-
7
.
19.
Devuyst
O
,
Olinger
E
,
Webers
S
,
Eckardt
KU
,
Kmoch
S
,
Rampoldi
L
,
Autosomal dominant tubulointerstitial kidney disease
.
Nat Rev Dis Primers
.
2019
;
5
(
1
):
60
.
20.
Kirby
A
,
Gnirke
A
,
Jaffe
DB
,
Barešová
V
,
Pochet
N
,
Blumenstiel
B
,
Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing
.
Nat Genet
.
2013
;
45
(
3
):
299
303
. .
21.
Ekici
AB
,
Hackenbeck
T
,
Morinière
V
,
Pannes
A
,
Buettner
M
,
Uebe
S
,
Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin
.
Kidney Int
.
2014
;
86
(
3
):
589
99
. .
22.
Olinger
E
,
Hofmann
P
,
Kidd
K
,
Dufour
I
,
Belge
H
,
Schaeffer
C
,
Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1
.
Kidney Int
.
2020
;
98
(
3
):
717
31
. .
23.
Capellani
D
,
Brancatella
A
,
Kaufmann
M
,
Minucci
A
,
Vignali
E
,
Canale
D
,
Hereditary hypercalcemia caused by a homozygous pathogenic variant in the CYP24A1 gene: a case report and review of the literature
.
Case Rep Endocrinol
.
2019
;
2019
:
4982621
.
24.
Schlingman
KP
,
Kaufmann
M
,
Weber
S
,
Irwin
A
,
Goos
C
,
John
U
,
Mutations in the CYP24A1 and idiopathic infantile hypercalcemia
.
N Engl J Med
.
2011
;
365
(
5
):
410
21
.
25.
Figueres
ML
,
Linglart
A
,
Bienaime
F
,
Allain-Launay
E
,
Roussey-Kessler
G
,
Ryckewaert
A
,
Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations
.
Am J Kidney Dis
.
2015
;
65
(
1
):
122
6
. .
26.
De Paolis
E
,
Scaglione
GL
,
De Bonis
M
,
Minucci
A
,
Capoluongo
E
.
CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype
.
Clin Chem Lab Med
.
2019
;
57
(
1
):
1650
67
. .
27.
Jais
JP
,
Knebelmann
B
,
Giatras
I
,
De Marchi
M
,
Rizzoni
G
,
Renieri
A
,
X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males
.
J Am Soc Nephrol
.
2000
;
11
(
4
):
649
57
.
28.
Bekheirnia
MR
,
Reed
B
,
Gregory
MC
,
McFann
K
,
Shamshirsaz
AA
,
Masoumi
A
,
Genotype-phenotype correlation in X-linked Alport syndrome
.
J Am Soc Nephrol
.
2010
;
21
(
5
):
876
83
.
29.
Nozu
K
,
Nakanishi
K
,
Abe
Y
,
Udagawa
T
,
Okada
S
,
Okamoto
T
,
A Review of clinical characteristics and genetic backgrounds in Alport syndrome
.
Clin Exp Nephrol
.
2019
;
23
(
2
):
158
68
. .
30.
Cocchi
E
,
Nestor
JG
,
Gharavi
AG
.
Clinical genetic screening in adult patients with kidney disease
.
Clin J Am Soc Nephrol
.
2020
;
15
(
10
):
1497
510
. .
31.
Dvela-Levitt
M
,
Kost-Alimova
M
,
Emani
M
,
Kohnert
E
,
Thompson
R
,
Sidhom
EH
,
Small molecule targets TMED9 and promotes lysosomal degradation to reverse proteinopathy
.
Cell
.
2019
;
178
(
3
):
521
35.e23
. .
32.
Daga
A
,
Majmundar
AJ
,
Braun
DA
,
Gee
HY
,
Lawson
JA
,
Shril
S
,
Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis
.
Kidney Int
.
2018
;
93
(
1
):
204
13
. .
33.
Jobst-Schwan
T
,
Pannes
A
,
Schlingmann
KP
,
Eckardt
KU
,
Beck
BB
,
Wiesener
MS
,
Discordant clinical course of vitamin-D-hydroxylase (CYP24A1) associated hypercalcemia in two adult brothers with nephrocalcinosis
.
Kidney Blood Press Res
.
2015
;
40
(
5
):
443
51
. .
34.
Janiec
A
,
Halat-Wolska
P
,
Obrycki
L
,
Ciara
E
,
Wójcik
M
,
Pludowski
P
,
Long-term outcome of the survivors of infantile hypercalcemia with CYP24A1 and SLC34A1 mutations
.
Nephrol Dial Transpl
.
2020
:
gfaa178
. Epub ahead of print.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.